Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma
Table 4
Outcomes of antiviral therapy in patients with HBV-related advanced HCC, as indicated by the mean reduction in serum DNA, HBV DNA suppression, undetectable HBV-DNA, and HBe seroconversion.
TLV (14)
ETV (11)
value
HBV DNA concentration, mean (SD), ( IU/mL)
4th week
3.38 ± 0.58
3.72 ± 0.94
0.328
12th week
3.20 ± 1.32
2.15 ± 0.94
0.178
24th week
1.76 ± 1.54
1.39 ± 1.04
0.697
HBV DNA suppression (below 2000 IU/mL)
4th week
4/12 (33.3%)
4/11 (36.3%)
0.611
12th week
3/4 (75%)
6/7 (85.7%)
0.400
24th week
3/3 (100%)
2/3 (66.6%)
0.500
Nondetectable HBV DNA (below 20 IU/mL)
4th week
0/12
0/9
12th week
1/4 (25%)
3/7 (42.8%)
0.424
24th week
1/3 (33.3%)
1/3 (33.3%)
0.800
HBe seroconversion
4th week
1/12 (8.3%)
0/9
0.560
12th week
0/4
0/7
24th week
0/3
0/3
Antiviral resistance
0
0
Hepatitis flare up
0
0
Variables are expressed as mean ± standard deviation (SD) or (%). Hepatitis flare up was defined as the elevation of alanine aminotransferase (ALT) level to more than 10 times the upper normal limit. TLV, telbivudine; ETV, entecavir; and HBeAg, hepatitis B e antigen.
